Nirvana Life Sciences Inc. announced a CAD 0.05 unit private placement on May 10, 2023. Each unit consisting of one common share and one half common share purchase warrant, each full warrant exercisable for an additional common share for aggregate gross proceeds of CAD 320,000. The company will now issue 6,400,000 common shares and 3,200,000 common share purchase warrants, each warrant being exercisable at CAD 0.15 per common share for a period of 24 months from date of issuance.

On the same date, The company received investment in its first tranche closing.